Amendment to Merger Agreement

Drugs Made In America Acquisition Corp. (DMAA) and Power Analytics Global Corp (PAGC) have entered into Amendment No. 3 to their Merger Agreement, originally dated April 29, 2026. Key amendments include changes to the treatment of former sponsor/founder shares, with provisions for forfeiture and earnout vesting. The company also agreed to a cash tender offer, exchange offer, or consent solicitation for outstanding publicly held rights, with a price range of $0.25 to $0.35 per right. Merger consideration calculations will now reference the Company’s fully diluted shares outstanding. The amendment also permits additional financings prior to closing. A potential three-party business combination is being negotiated, with Amendment No. 3 pre-approving a contingent Amendment No. 4. Minimum cash provisions have been restated with a target of $30,000,000 and a floor of $15,000,000. Related-party protections have been implemented due to common principal ownership between PAGC and BV Advisory Partners, LLC, requiring a fairness opinion from an independent investment banking firm and independent director oversight for certain determinations.